Xenón Serrano Martín

Prof. Dr. Xenón Serrano Martín

Grupo Leti S.A.V, Caracas, Distrito Capital, Venezuela

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Experimental Parasitology
Verified
Journal Article
Closed access
JLJacques Leañez
Jacques Leañez
JNJorge Nuñez
Jorge Nuñez
YGYael García-Marchan
Yael García-Marchan
FSFelipe Sojo
Felipe Sojo
FAFrancisco Arvelo
Francisco Arvelo
XMXenón Serrano Martín
Xenón Serrano Martín

30 August 2024 in Molecules
Verified
Journal Article
Open access
PDF file
AMAli Mijoba
Ali Mijoba
NGNereida Parra Gimenez
Nereida Parra Gimenez
EFEsteban Fernandez-Moreira
Esteban Fernandez-Moreira
HPHegira Hegira Ramírez Padilla
Hegira Hegira Ramírez Padilla
XMXenón Serrano Martín
Xenón Serrano Martín
Jaime CharrisJaime Charris
Jaime Charris
The aim of this work was to obtain and evaluate, as antiprotozoals, new derivatives of benzoate imidazo-1,3,4-thiadiazole 18–23 based on the concepts of molecular repositioning and hybridization. In the design of these compounds, two important pharmacophoric subunits of the fexnidazole prototype were used: metronidazole was used as a repositioning molecule, p-aminobenzoic acid was incorporated as a bridge group, and 1,3,4-thiadiazole group was incorporated as a second pharmacophore, which at position 5 has an aromatic group with different substituents incorporated. The final six compounds were obtained through a five-step linear route with moderate to good yields. The biological results demonstrated the potential of this new class of compounds, since three of them 19–21 showed inhibitory activity on proliferation, in the order of 50%, in the in vitro assay against epimastigotes of T. cruzi (Strain Y sensitive to nifurtimox and benznidazole) and promastigotes of L. donovani, at a single concentration of 50 μM.

31 August 2022 in Molecules
Verified
Journal Article
Open access
PDF file
ZMZuleyma Blanco Marquez
Zuleyma Blanco Marquez
EFEsteban Fernandez-Moreira
Esteban Fernandez-Moreira
MMMichael Rodney Mijares
Michael Rodney Mijares
CCCarmen Celis
Carmen Celis
Gricelis Patricia MartinezGricelis Patricia Martinez
Gricelis Patricia Martinez
Jaime CharrisJaime Charris
Jaime Charris
The coexistence of leishmaniasis, Chagas disease, and neoplasia in endemic areas has been extensively documented. The use of common drugs in the treatment of these pathologies invites us to search for new molecules with these characteristics. In this research, we report 16 synthetic chalcone derivatives that were investigated for leishmanicidal and trypanocidal activities as well as for antiproliferative potential on eight human cancers and two nontumor cell lines. The final compounds 8–23 were obtained using the classical base-catalyzed Claisen–Schmidt condensation. The most potent compounds as parasiticidal were found to be 22 and 23, while compounds 18 and 22 showed the best antiproliferative activity and therapeutic index against CCRF-CEM, K562, A549, and U2OS cancer cell lines and non-toxic VERO, BMDM, MRC-5, and BJ cells. In the case of K562 and the corresponding drug-resistant K562-TAX cell lines, the antiproliferative activity has shown a more significant difference for compound 19 having 10.3 times higher activity against the K562-TAX than K562 cell line. Flow cytometry analysis using K562 and A549 cell lines cultured with compounds 18 and 22 confirmed the induction of apoptosis in treated cells after 24 h. Based on the structural analysis, these chalcones represent new compounds potentially useful for Leishmania, Trypanosoma cruzi, and some cancer treatments.